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A B S T R A C T
Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a
cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS).
Methods: The European Registry of OAPS became a registry within the framework of the European Forum on
Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout
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Pregnancy autoimmune disorders Europe have collaborated to carry out this registry. Cases with obstetric complaints related to antiphospholipid
antibodies (aPL) who tested positive for aPL at least twice were included prospectively and retrospectively. The
seven-year survey results are reported.
Results: 1000 women with 3553 episodes were included of which 2553 were historical and 1000 were latest
episodes. All cases fulfilled the Sydney classification criteria. According to the laboratory categories, 292
(29.2%) were in category I, 357 (35.7%) in IIa, 224 (22.4%) in IIb and 127 (12.7%) in IIc. Miscarriages were the
most prevalent clinical manifestation in 386 cases (38.6%). Moreover, the presence of early preeclampsia (PE)
and early foetal growth restriction (FGR) appeared in 181 (18.1%) and 161 (16.1%), respectively. In this series,
448 (44.8%) women received the recommended OAPS treatment. Patients with recommended treatment had a
good live-birth rate (85%), but worse results (72.4%) were obtained in patients with any treatment (low-dose
aspirin (LDA) or low-molecular-weight heparin (LMWH) not on recommended schedule, while patients with no
treatment showed a poor birth rate (49.6%).
Conclusion: In this series, recurrent miscarriage is the most frequent poor outcome. To avoid false-negative
diagnoses, all laboratory category subsets were needed. OAPS cases have very good foetal-maternal outcomes
when treated. Results suggest that we were able to improve our clinical practice to offer better treatment and
outcomes to OAPS patients.
1. Introduction
The antiphospholipid syndrome (APS) is an autoimmune disease
defined by the presence of vascular thrombosis and/or obstetric com-
plications related to antiphospholipid antibodies (aPL) [1]. The Inter-
national consensus conducted in Sydney in 2006 summarises obstetric
complications in recurrent first trimester miscarriage, foetal losses,
stillbirth, early and severe preeclampsia or prematurity (< 34weeks)
due to placental dysfunction [2]. However, there are cases known to
have obstetric antiphospholipid syndrome (OAPS) [3] without a pre-
vious thrombotic history. Placental insufficiency plays a pivotal role in
the pathogenesis of pregnancy complications partly due to the detri-
mental effects of aPL, from implantation and placenta genesis to de-
livery [4]. Levy et al. [5] demonstrated that decidual or placental
thrombosis could not be confirmed in almost 50% of cases, suggesting
an apparent silent inflammatory mechanism [6]. This theory has been
demonstrated in subsequent research [7]. It has been postulated that
complement activation and secondary endothelial disruption may im-
pair invasion and trophoblast function [8]. Other pathways of in-
flammation could involve tissue factor over-expression in neutrophils
and monocyte cells [9]. They can also involve the release of neutrophil
extracellular trap and interleukin-8 [10], the upregulation of the me-
chanistic target of the rapamycin (mTOR) complex on endothelial cells
[11] and the reduced activity of activated C protein [12], despite a
negative imbalance of angiogenic factors [13], still in the absence of
thrombosis.
There is evidence that APS is the most frequently treatable acquired
cause during pregnancy [14], although it is known that the classic form
and the obstetric one have different rates of thrombosis [15], response
to treatment [16] or follow-up [17]. Those incomplete forms (by
meeting neither the clinical nor the laboratory criteria) represent a
special challenge for the clinician [18], as there is increasing evidence
that patients with low aPL titers can experience poor pregnancy out-
comes similarly to high-titer patients [19]. In the same way, women
with incomplete clinical forms benefit from treatment, having better
prognosis than women without treatment [20]. Thus, at the recent 14th
International Congress on Antiphospholipid Antibodies Task Force Re-
port on Obstetric APS and the Update on Antiphospholipid Syndrome in
2017, ten papers concluded that new information should be obtained
mainly through randomised clinical trials and large series of patients
recruited from multicenter registries [21,22]. In an attempt to confirm
the hypothesis that OAPS cases are different from “classical” APS, we
assessed the clinical features, laboratory data, treatment, foetal and
maternal outcomes, as well as the long-term follow-up of 1000 women
with pure OAPS.
2. Patients and methods
2.1. Patients
In order to collect as much information as possible about a het-
erogeneous entity such as the obstetric antiphospholipid syndrome
(OAPS), a simple and accessible web register was set up where all ex-
perts could introduce their cases, allowing future knowledge on this
disease. The website and database have been accessible ever since June
2010. Since then, patients have been included retrospectively and
prospectively on the website www.euroaps.wordpress.com.
2.2. Study design
Thirty tertiary referral centres in twelve European countries and
two centres in Argentina are participating in the registry. The members
in charge of treating these patients are experts in the management of
the APS. To date, the cohort has consisted of 1640 cases, 640 of which
were excluded after a thorough revision and 1000 met the proposed
Sydney classification criteria. Obstetrics, hematology, internal medi-
cine, autoimmune diseases and rheumatology are the departments in-
volved.
The database has been created with all those centers that shared
information on the online register. A total amount of 150 items have
been introduced, with variables such as “epidemiological data”, “pre-
vious pregnancies”, “current pregnancy”, “foetal status”, “puerperium”,
“laboratory data” and “treatment schedule” among others, many of
which were mandatory to advance in the next register steps.
Participants have been encouraged to include both complete (pure
OAPS) and incomplete cases. These incomplete cases (640 women) will
be further analysed elsewhere. All introduced patients automatically
received an encryption code to preserve privacy and personal data.
This registry has the approval and benefit of both the Ethics
Committee and Review Board of Vall d'Hebron University Hospital and
the University Departments of Medicine and Obstetrics of the
Universitat Autònoma de Barcelona.
2.2.1. Inclusion clinical criteria
Women meeting the clinical criteria of the Sydney classification
have been introduced in the registry, this is to say, patients with 3 or
more consecutive first-trimester miscarriages, foetal losses> 11weeks
or prematurity due to presence of placental vasculopathy (less than
week 34). These women had not previously presented any major
thrombotic event. All previous pregnancies have also been introduced,
each one coded as an isolated episode. Subsequently, the current ge-
station has also been registered. All adverse obstetric events presented
have been documented.
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2.2.2. Inclusion laboratory criteria
Presence of a positive antiphospholipid antibody: lupus antic-
oagulant (LA), IgM anticardiolipin (IgM aCL) or IgG anticardiolipin
(IgG aCL) and IgM anti-beta2-glycoprotein 1 (IgM anti-β2GPI) or IgG
anti-beta2-glycoprotein 1 (IgG anti-β2GPI) is required in two or more
blood tests, separated in time by more than twelve weeks. They were
divided by laboratory categories as category I (more than one aPL being
positive); Category II (only one aPL positivity); IIa: LA+, IIb: IgM aCL
or IgG aCL or both positive, IIc: IgM anti-β2GPI or IgG anti-β2GPI or
both positive.
2.2.3. Exclusion clinical criteria
Women not meeting the Sydney diagnostic criteria have been ex-
cluded, as, for instance, those with<3 consecutive miscarriages or
those with establishment of placental pathology appearing beyond
week 34. There may have been patients presenting another clinical
presentation not included in the Sydney criteria, as long as they have
showed other typical clinical criteria. However, patients who have had
abortions due to a chromosomal, infectious, hormonal or anatomical
cause have also been excluded, as well as those with active infection for
HBV, HCV, HIV, syphilis or tuberculosis.
2.2.4. Exclusion laboratory criteria
Following the Sydney recommendations, those patients with
medium or low aPL titers as well as those presenting atypical aPL such
as antithrombin (aPT) or antiannexin A5 (a-A5) have been excluded.
2.2.5. Other laboratory-analysed parameters
Most of the centres also tested for inherited thrombophilia: protein
S, antithrombin, protein C, resistance to activated C protein, homo-
cysteine and gene polymorphisms of methylen-tetrahydropholate re-
ductase (MTHFR), FV Leiden and FII G20210A mutations. Also, a
complete panel of autoantibodies has been performed on most of the
patients: antinuclear antibodies (ANAs), ds-antiDNA antibodies and
antithyroid antibodies. Some patients have also been tested for anti-
bodies to extractable nuclear antigens as Ro/La/RNP/Sm/Scl-70/cen-
tromere/Jo-1. Furthermore, almost all patients have been checked for
C3 and C4 complement levels, serum protein electrophoresis, vitamin
D2 levels or non-criteria aPL.
2.2.6. Miscellaneous
In order to correctly gauge the magnitude of obstetric complica-
tions, up to 25 different complications have been categorised: recurrent
miscarriage, foetal loss, stillbirth, early-PE, late-PE, early-FGR, late-
FGR, early-HELLP, late-HELLP, early-eclampsia, late-eclampsia, other
ultrasonographic signs of placental vasculopathy (abnormal uterine
blood flow, abnormal foetal placental flow, abruptio placentae, pla-
cental haematoma), arterial or venous thrombosis during pregnancy,
chorioamnionitis, IVF failure, only one or two miscarriages, perinatal
death, prematurity (live birth before 34 weeks), preterm birth (before
37 weeks) and maternal death.
Puerperium follow-up has also been introduced, highlighting the
possible shift to an autoimmune disease or thromboembolic event. In
addition, three different heparin prophylactic doses have been defined:
low, medium and high prophylactic doses, together with therapeutic
ones. According to the most common LMWH used (enoxaparin), the
doses have been defined as low prophylactic at 20mg/day, medium at
40mg/day and high at 1mg/kg/day. The doses of 1mg/kg/bid have
been labeled as therapeutic.
2.3. Assays
Standard screening assays were used to detect LA according to the
Sydney recommendations of the ISTH Subcommittee, and aPL titers
have been analysed by the ELISA methods. The results of aCL have been
expressed as immunoglobulin G (GPL) or immunoglobulin M (MPL)
using international references. The results of anti-β2GPI IgG/IgM assays
were calculated arbitrary units using a standard curves obtained from a
pool of positive samples accurately calibrates.
In accordance with the Sydney recommendations, all plasmas have
been analysed for the four-solid-phase aPL antibody by methods based
on calibration curves established by the Sydney standards. The cut-off
values used for medium-high titers of aCL antibodies were 40 GPL and/
or MPL and low titers between 15 and 39 and/or MPL, before February
2006. From February 2006 on, in accordance with the Sydney classi-
fication criteria, the cut-off values used for medium/high titers for both
aCL and antiβ2GPI antibodies were calculated using either the Sydney
standards or the 99th percentile obtained by testing age-matched
healthy women. The aPL positivity had to have been present at least
twice, with a minimum interval of 12 weeks. According to the experts'
recommendations, investigators are strongly advised to classify APS
patients, when studied, into different categories: I, more than one la-
boratory criteria present, for any combination; IIa, LA present alone;
IIb, aCL antibody present alone; IIc, anti-β2glycoprotein-I antibody
present alone.
2.4. Statistical analysis
Values are expressed as mean, standard deviation, median, 25th and
75th percentiles (Q1 and Q3, respectively), the sum and extreme values
(minimum and maximum) for continuous variables, and number and
percentages for qualitative variables. A student's t-test was used to
compare values following normal distribution, while the
Mann–Whitney–Wilcoxon's test or the Kruskal–Wallis test was used for
data not following a normal distribution. The chi-square test and
Fisher's exact test were used to compare categorical variables. The
univariate logistic regression analysis was used to estimate the risks of
analytical parameters in the presence of the studied morbidities. The
statistical software SPSS (ver.22.0.0.0) was used to analyse the datasets
(Clinical Research Unit, Althaia Healthcare University Network of
Manresa and Barcelona).
3. Results
3.1. Patient baseline clinical characteristics
The patients' demographic data and their baseline characteristics
are explained in Table 1. Overall, 5229 pregnancies of 1640 women
were analysed. Only 1000 women with 3553 episodes fulfilled the
Sydney Criteria, being included for definitive analysis. Most women
were Caucasian (72.5%), non-smokers (84.8%) and with a normal body
mass index. Interestingly, women's age of diagnosis (35.2 years) was in
an interval age in which good fertility is still conserved. However, mean
pregnancy failures were 2.19 for each patient. Regarding the wide-
spread belief that obesity is a major risk factor in pregnancy, we have
found only 8.6% obese patients in our registry. On the other hand, 76
women (7.6%) had systemic lupus erythematosus (SLE) and 93 (9.3%)
clinical or subclinical autoimmune thyroid abnormalities. Concerning
their previous obstetric morbidity, 27% women had RM, 17% foetal
loss, 18.5% stillbirth, 4.9% early PE and 5.4% early FGR. According to
inherited thrombophilic disorders, we have found 15.9% of patients
carrying any of them. Regarding their current obstetric complications,
650 women (65%) had no pregnancy complications, being prematurity
(20.7%), early PE (14.3%) and miscarriage (13.2%) the most prevalent
ones. All results are depicted in Table 1.
3.2. Laboratory characteristics and obstetric-related morbidities
3.2.1. Laboratory categories and obstetric morbidities
Regarding laboratory categories, we obtained a higher prevalence of
category II (708 cases) (70.8%) over category I (292 cases) (29.2%).
Within category I, double positivity (184 cases) (18.4%) showed a
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higher prevalence over triple positivity (110 cases) (11%). Attending to
category II we have found that category IIa (single LA positivity) was
significantly the most prevalent with 356 cases (50.42% of category II
and 35.6% of all cases). The other categories: IIb (single aCL positivity)
and IIc (single anti-β2GPI positivity) had 224 (22.4%) and 126 (12.6%)
cases, respectively. We can find results deployed in Table 2. Referring to
the obstetric-related morbidities, we have found that 651 patients
(65.1%) presented no obstetric complications in their current preg-
nancy. Going on with the current pregnancy complications (latest
pregnancy), we can see how prematurity was the most frequent ap-
pearing alone in 241 cases (24.1%) or in combination with PE in 128
cases (12.8%) or FGR in 107 cases (10.7%). Full combination (pre-
maturity with PE and FGR) was found in 55 cases (5.5%). We have
observed that category I and IIa presented similar percentages in the
prematurity obstetric-related complications. Regarding miscarriages,
the main laboratory categories were IIa and IIb with 44 and 39 cases
each, respectively. In case of foetal loss and stillbirth, we also found
similar results in category I and IIa. Otherwise, according to all ob-
stetric complications (all historical pregnancies), we stated that mis-
carriages, foetal losses and stillbirths were significantly the most pre-
valent obstetric complications. At this point we found 386 (38.6%)
miscarriages, 253 (25.3%) foetal losses and 230 (23%) stillbirths, with
similar laboratory category percentages. All data is detailed in Tables 3
and 4.
3.2.2. Associated inherited clot pathway disorders
We have found that inherited thrombophilia was positive in 159
(15.9%) women excluding those who tested positive for heterozygosis
C677-MTHFR. Most of those women had activated C-protein resistance/
Leyden factor V mutation 44/159 (27.67%), C677-MTHFR mutation in
homozygosis 31/159 (19.49%) and protein C deficiency 28/159
(17.61%). In all, 22 women (13.83%) had protein S deficiency, 13
(8.17%) antithrombin III deficiency, 12 (7.54%) prothrombin G20210a
mutation, 5 (3.14%) hyperhomocysteinemia, and 4 (2.51%) factor XII
deficiency.
3.2.3. Associated connective tissue autoantibodies
ANAs were positive in 295 patients (29.5%), 128 of them had
speckled pattern, 106 were homogeneous, 38 nucleolar, 10 centromere,
9 rim and 3 diffuse. Anti-dsDNA was positive in 35 of those patients.
Interestingly, the most prevalent extractable nuclear antigens (ENAs)
were anti-Ro52 antibody in 42 cases (combined with anti-Ro60 in 30
cases). Anti-Sm was found in 38 cases and RNP in 28 cases.
3.2.4. Other laboratory data
Plasma complement levels were analysed in 850/1000 (85%) cases.
Of these, 167/850 (19.64%) had low C3 levels and 148/850 (17.41%)
had low C4 levels. Furthermore, 97 women had both C3 and C4 low
levels (11.41%). Overall, 218/850 (25.64%) women had low values.
Vitamin D2 deficiency was found (< 20 ng/mL) in 279 (27.9%)
women.
3.3. Histopathological findings
We have observed that placental biopsy is not a routine way in
clinical practice, since those results appear in only 159/1000 cases
(15.9%). We would like to highlight that infarcts or thrombus presence
was found in 68 (42.76%) and 30 cases (18.86%), respectively, and in
contrast, inflammatory findings as fibrin or villitis were found in 37
(29.83%) and 28 (17.61%) cases, respectively. All results are depicted
in Table 8.
3.4. Foetal-maternal outcomes
The main outcome studied was the foetal live-birth. Regardless the
type of administered treatment, live-birth was achieved in 728/1000
cases (72.8%), while in 272/1000 cases (27.2%) was not. We have
observed a lower incidence of maternal thrombosis in all women stu-
died with 25 venous and 6 arterial thromboses, respectively, being
puerperal thrombosis the most frequent manifestation. We also en-
countered an evolution to SLE in 54 (5.4%) cases. All data is sum-
marised in Table 5.
3.5. Treatment schedules related to obstetric complications and maternal-
foetal outcomes
We have divided the successful (live-birth patients) and un-
successful (no live-birth patients) according to whether they were under
treatment or not. In brief, successful cases were treated in 614/728
(84.54%) and 114/728 (15.65%) were not. In addition, those treated
successfully were under recommended regime (on preconcepcional AAS
and LMWH prophylactic dose from the first trimester) in 381/614
(62.05%). Unsuccessful cases were under treatment in 156/272
(57.35%) and 116/272 (42.64%) were not. In closer detail, we found an
in crescendo number of live births among patients with no treatment
(114 live births), non-standard treatment regime (233 live births), and
standard treatment regime (381 live births). In the same way, we ob-
tained similar progression regarding newborn weight (2203 g in un-
treated patients, 2431 g in non-standard treated patients and 2907 g in
standard-treated patients). According to the weeks of delivery, the
higher prevalence of prematurity appeared in untreated patients with
59.6% of the cases in the whole group. There were more frequent births
after 24 weeks in patients with a recommended regime (86.8%) than in
patients with a non-standard treatment (77.6%) and untreated patients
(62.6%). On the other hand, if we study obstetric complications, the
correlation is clearly opposed. Untreated patients presented a higher
Table 1
Main demographic characteristics and obstetric background of these 1000
women.
Age (years) mean ± SD 35.20 ± 5.94
Ethnicity n (%)
African 21 (2.1)
Afro American/Caribbean 6 (0.6)
American (Latino) 159 (15.9)
Asian 5 (0.5)
Caucasian 725 (72.5)
Semitic/Arab 81 (8.1)
Smoking habit n (%)
Yes 152 (15.2)
No 848 (84.8)
B.M.I. mean ± SD 24.16 (4.68)
Cardiovascular risk factors n (%)
Obesity 86 (8.6)
High Blood Pressure 48 (4.8)
Dyslipidaemia 22 (2.2)
Diabetes mellitus 18 (1.8)
Previous diseases n (%)
SLE 76 (7.6)
Thyroida 93 (9.3)
Kidney disease 33 (3.3)
Previous poor obstetric outcome n (%)
Recurrent miscarriage < 10weeks 270 (27)
Foetal loss 170 (17)
Stillbirth 185 (18.5)
Early PE (< 34w) 49 (4.9)
Early FGR (< 34w) 52 (5.2)
Early HELLP (< 34w) 12 (1.2)
Total pregnancy failures mean±SD 2.19 ± 1.59
Previous successful pregnancies mean± SD 0.6 ± 0.85
Inherited thrombophilia n (%)
No 841 (0.84)
Yes 159 (0.15)
BMI: Body mass index; SD: Standard deviation; SLE: Systemic lupus er-
ythematosus; PE: Preeclampsia; FGR: Foetal growth restriction.
a Includes: hypothyroidism, subclinical hypothyroidism, and antithyroid
antibodies.
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prevalence of early PE (41.2%) and FGR (27.2%) than correctly treated
patients (6.6% and 4.2% of PE and FGR, respectively). Moreover, there
were more miscarriages (22.6%), foetal losses (14.8%) and stillbirths
(14.2%) in untreated patients than in patients with a recommended
regime (9.2% miscarriages, 4% foetal losses and 1.8% stillbirths). All
data is detailed in Tables 6 and 7.
4. Discussion
Prior to this publication, we only found case series with<300
Table 2
Laboratory categories of the Registry of women with OAPS.
Lab category Class and isotype of aPL N n/N(%)
I 294 29.4%
Triple positivity 110/294/1000 (37.41) (11)
LA+ aCL IgG+ IgM+anti-β2GPI-IgG+ IgM+ 21
LA+ aCL IgG+ IgM+anti-β2GPI-IgG+ IgM– 2
LA+ aCL IgG+ IgM+anti-β2GPI-IgG – IgM+ 4
LA+ aCL IgG+ IgM – anti-β2GPI-IgG+ IgM + 5
LA+ aCL IgG – IgM+anti-β2GPI-IgG+ IgM+ 1
LA+ aCL IgG – IgM+anti-β2GPI-IgG – IgM+ 21
LA+ aCL IgG+ IgM – anti-β2GPI-IgG+ IgM– 51
LA+ aCL IgG – IgM+anti-β2GPI-IgG+ IgM– 5
Double positivity 184/294/1000 (62.58) (18.4)
LA+ aCL IgG+ IgM+ 14
LA+ aCL IgG+ IgM– 48
LA+ aCL IgG – IgM+ 32
LA+ anti-β2GPI-IgG+ IgM+ 2
LA+ anti-β2GPI-IgG+ IgM– 24
LA+ anti-β2GPI-IgG – IgM+ 11
aCL IgG+ IgM+anti-β2GPI-IgG+ IgM+ 4
aCL IgG+ IgM+anti-β2GPI-IgG+ IgM– 2
aCL IgG+ IgM+anti-β2GPI-IgG – IgM+ 2
aCL IgG – IgM+anti-β2GPI-IgG+ IgM+ 2
aCL IgG+ IgM – anti-β2GPI-IgG+ IgM– 24
aCL IgG+ IgM – anti-β2GPI-IgG – IgM+ 5
aCL IgG – IgM+anti-β2GPI-IgG – IgM+ 13
aCL IgG – IgM+anti-β2GPI-IgG+ IgM– 1
Lab Category Class and isotype of aPL N N (%)
II 706 70.6%
IIa Lupus Anticoagulant 356/706/1000 (50.42) (35.6)
IIb Anticardiolipin antibodies 224/706/1000 (31.72) (22.4)
IgG Isotype 116
IgM Isotype 75
IgG/IgM 33
IIb Anti-β2GPI antibodies 126/706/1000 (17.84) (12.6)
IgG Isotype 63
IgM Isotype 45
IgG/IgM 18
N: number of cases; OAPS: obstetric antiphospholipid syndrome.
Table 3
Detailed currenta obstetric complications in this OAPS series (N=1000). A general view and related to laboratory categories.
All Cat. I Cat. IIa Cat. IIb Cat. IIc p-Value
N=1000 n=294 n=356 n=224 n=126
Complications 651 (65.1) 207 (70.4) 230 (64.6) 135 (60.3) 79 (62.7) 0.098
Prematurity 241 (24.1) 79 (26.9) 92 (25.8) 40 (17.9) 30 (23.8) 0.086
Miscarriage (latest) 118 (11.8) 23 (7.8) 44 (12.4) 39 (17.4) 12 (9.5) 0.007
Foetal loss 84 (8.4) 31 (10.5) 24 (6.7) 15 (6.7) 14 (11.1) 0.166
Stillbirth 56 (5.6) 22 (7.5) 26 (7.3) 4 (1.8) 4 (3.2) 0.009
PE (< 34w) 143 (14.3) 46 (15.6) 59 (16.6) 23 (10.3) 15 (11.9) 0.139
PE (> 34w) 36 (3.6) 14 (4.8) 14 (3.9) 6 (2.7) 2 (1.6) 0.349
FGR (< 34w) 116 (11.6) 41 (13.9) 45 (12.6) 13 (5.8) 17 (13.5) 0.021
FGR (> 34w) 39 (3.9) 14 (4.8) 12 (3.4) 11 (4.9) 2 (1.6) 0.353
HELLP (< 34w) 27 (2.7) 7 (2.4) 17 (4.8) 1 (0.4) 2 (1.6) 0.013
HELLP (> 34w) 2 (0.2) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.8) 0.283
Prematurity+ PE 128 (12.8) 36 (12.2) 54 (15.2) 22 (9.8) 16 (12.7) 0.302
Prematurity+ FGR 107 (10.7) 34 (11.6) 43 (12.1) 14 (6.3) 16 (12.7) 0.107
Prematurity+ PE+FGR 55 (5.5) 15 (5.1) 23 (6.5) 7 (3.1) 10 (7.9) 0.204
Abnormal uterine blood flow 78 (7.8) 21 (7.1) 26 (7.3) 21 (9.4) 10 (7.9) 0.783
Abnormal fetoplacentary flow 17 (1.7) 5 (1.7) 7 (2.0) 3 (1.3) 2 (1.6) 0.985
Placental haematoma 13 (1.3) 3 (1.0) 5 (1.4) 0 (0) 5 (4.0) 0.015
Abruptio placentae 10 (1.0) 1 (0.3) 4 (1.1) 2 (0.9) 3 (2.4) 0.254
OAPS: Obstetric Antiphospholipid Syndrome; Prematurity: Born alive< 34weeks; FGR: Foetal Growth Restriction; PE: Pre- eclampsia; Cat: Laboratory category.
a Latest pregnancy.
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reported OAPS cases [23–25]. In our 1.000-patient analysis, 72.5%
were Caucasian, non-smokers (84.8%) and middle-aged (35.2 years).
There was no high rate of comorbidities, being thyroid disease and SLE
the most prevalent. Certainly, in patients carrying aPL it is possible to
stay in a grey zone with other autoimmune diseases [26]. Thus, a
genetic predisposition [27] and a trigger that may damage endothelial
surface [28] with aPL generation could explain its heterogeneous pre-
sentation. Furthermore, we have observed that there were a few cases
that presented other clinical manifestations, such as migraine (34 cases)
and high blood pressure (48 cases), reinforcing the theory of en-
dothelial damage [29]. All of our patients have been referred from
specialized units in different countries throughout Europe. This
Table 4
Detailed all obstetric complications in this OAPS series (N=1000). A general view and related to laboratory categories.
All Cat. I Cat. IIa Cat. IIb Cat. IIc p-Value
N=1000 n=294 n=356 n=224 n=126
Prematurity 285 (28.5) 89 (30.3) 112 (31.5) 47 (21.0) 37 (29.4) 0.041
Miscarriage×3 386 (38.6) 102 (34.7) 136 (38.2) 105 (46.9) 43 (34.1) 0.024
Foetal loss 253 (25.3) 84 (28.6) 79 (22.2) 57 (25.4) 33 (26.2) 0.315
Stillbirth 230 (23.0) 65 (22.1) 87 (24.4) 49 (21.9) 29 (23.0) 0.871
PE (< 34w) 181 (18.1) 59 (20.1) 74 (20.8) 26 (11.6) 22 (17.5) 0.031
PE (> 34w) 46 (4.6) 16 (5.4) 16 (4.5) 8 (3.6) 6 (4.8) 0.794
FGR (< 34w) 161 (16.1) 50 (17.0) 61 (17.1) 22 (9.8) 28 (22.2) 0.015
FGR (> 34w) 47 (4.7) 15 (5.1) 15 (4.2) 14 (6.3) 3 (2.4) 0.390
HELLP (< 34w) 35 (3.5) 8 (2.7) 19 (5.3) 6 (2.7) 2 (1.6) 0.109
HELLP (> 34w) 3 (0.3) 2 (0.7) 0 (0.0) 0 (0.0) 1 (0.8) 0.172
Prematurity+ PE 160 (16.0) 47 (16.0) 70 (19.7) 23 (10.3) 20 (15.9) 0.029
Prematurity+ FGR 139 (13.9) 40 (13.6) 55 (15.4) 21 (9.4) 23 (18.3) 0.087
Prematurity+ PE+FGR 69 (6.9) 18 (6.1) 31 (8.7) 8 (3.6) 12 (9.5) 0.063
Ecographic signs of placental insufficiency (< 34w) 77 (7.7) 24 (8.2) 25 (7.0) 21 (9.4) 7 (5.6) 0.569
Ecographic signs of placental insufficiency (> 34w) 25 (2.5) 6 (2.0) 10 (2.8) 5 (2.2) 4 (3.2) 0.886
Placental haematoma 13 (1.3) 3 (1.0) 5 (1.4) 0 (0.0) 5 (4.0) 0.013
Abruptio placentae 10 (1.0) 1 (0.3) 4 (1.1) 2 (0.9) 3 (2.4) 0.256
Cat: laboratory aPL category; Prematurity: Born alive<34weeks; FGR: Foetal Growth Restriction; PE: Pre-eclampsia.
Table 5
Foetal and maternal outcomes related to this cohort of women.
n/N (%)
Live births 728/1000 (72.8)
No live births 272/1000 (27.2)
Maternal outcomes
Pregnancy thrombosis
Venous 6/1000 (0.6)
Arterial 0/1000 (0)
Puerperal thrombosis
Venous 19/1000 (1.9)
Arterial 6/1000 (0.6)
Evolvement into systemic diseases
SLE 54/1000 (5.4)
ITP 10/1000 (1.0)
PE: Preeclampsia; FGR: Foetal growth restriction; SLE: Systemic lupus er-
ythematosus; ITP: idiopathic thrombocytopenic purpura.
Table 6
Treatment regimes in this cohort of women.
Cases
n/N/N (%)
No treatment 230/1000 (23)
Treatment 770/1000 (77)
LDA alone 97/770 (12.59)
LDA alone preconceptional 46/97/770 (47.42) (5.97)
LMWH alone 39/770 (5.06)
LDA+LMWH /770/1000 (82.33) (63.4)
Recommended schedule 448/770/1000 (58.18) (44.8)
Other drugs
Progesterone during first trimester /770/1000 (18.18) (14)
Hydroxychloroquine 93/770/1000 (12.07) (9.3)
Prednisone 70/770/1000 (9.09) (7)
IVIGs 11/770/1000 (1.42) (1.1)
Anti-TNF 3/770/1000 (0.38) (0.30)
LDA: Low-dose aspirin; LMWH: Low molecular weight heparin; IVIGs: in-
travenous immunoglobulin; Recommended schedule: LDA
preconceptional + LMWH started preconceptional or in first trimester.
Table 7
Detailed currenta obstetric complications in this OAPS series (N=1000) ac-
cording to treatment compliance.
Treatment and
Recommended
regime
Treatment but no
Recommended
regime
No Treatment p-Value
n= 448 n=322 n=230
Miscarriage
(latest)
41 (9.2) 39 (12.1) 52 (22.6) <0.001
Foetal loss 18 (4.0) 32 (9.9) 34 (14.8) <0.001
Stillbirth 8 (1.8) 15 (4.7) 33 (14.3) <0.001
Weeks at
delivery
0–10 41 (9.8) 41 (12.7) 59 (25.7) <0.001
11–23 18 (4.0) 31 (9.6) 27 (11.7)
≥24 389 (86.8) 250 (77.6) 144 (62.6)
Live birth 381 (85.0) 233 (72.4) 114 (49.6) <0.001
Live birth
(yes)
n= 381 n=233 n=114
Preterm 103 (27.0) 121 (51.9) 75 (65.8) <0.001
Prematurity 67 (17.6) 99 (42.5) 68 (59.6) <0.001
PE (< 34w) 25 (6.6) 57 (24.5) 47 (41.2) <0.001
PE (> 34w) 18 (4.7) 10 (4.3) 8 (7.0) 0.524
FGR (< 34w) 16 (4.2) 50 (21.5) 31 (27.2) <0.001
FGR (> 34w) 25 (6.6) 10 (4.3) 4 (3.5) 0.304
HELLP
(< 34w)
6 (1.6) 10 (4.3) 7 (6.1) 0.020
HELLP
(> 34w)
0 (0.0) 1 (0.4) 1 (0.9) 0.229
New-bornsb n= 392 n=239 n=117
Weight of
new-born
(g)c
2907 2431 2203 <0.001
Prematurity: Born alive less or equal than 34weeks; FGR: Foetal Growth
Restriction; PE: Pre-eclampsia.
a Latest pregnancy.
b There are more new-borns than live births due to gemelar pregnancies.
c In grams.
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explains why a high percentage of patients had already been treated
(77%), thus obtaining a fair number of patients under the re-
commended regime (preconceptional LDA and prophylactic dose of
LMWH from the first trimester on in 44.8% of cases). We found 15.17%
of refractory cases among patients treated under recommended regime,
similar to the data published by Ruffatti et al. in their recent review
[23]. We would like to highlight that in the last 10 years (the time lapse
of this ongoing register); hydroxychloroquine has arrived as a pro-
mising new therapy for refractory OAPS [30]. Case-tailored manage-
ment was found probably because patients with less thrombotic events
observed came from these specialized centers. We only found 31 cases
(3.1%) in which thrombotic phenomena occurred, in contrast to what
was published by Drozidnsky et al., where the thrombosis rate reached
12% [31]. In any case and contrary to what was classically thought, it
seems that venous and/or arterial thromboses are not frequent com-
plications among the OAPS patients. In fact, opinion leaders in anti-
phospholipid antibodies are convinced that most cases will have only
obstetric complications with none or few thrombotic events [21],
showing a huge difference from primary APS and its thrombosis re-
currence [32]. As we can find in our series, placental histology re-
veals< 24.19% of cases with documented thrombosis, which correlates
with the previous studies from Out et al. [4]. Furthermore, we can see
how neutrophils lead patients into a pro-inflammatory state. In a mouse
model of SLE patients, this excessive amount of neutrophil extracellular
traps (NET) infiltrate the placenta, leading to vascular damage in pa-
tients with SLE [33]. Thus, the data on the registry support the defi-
nition that the obstetric antiphospholipid syndrome refers to women
with only obstetric aPL-related complaints and no history of past or
current thrombotic events at the time of diagnosis [34].
Regarding the most prevalent clinical manifestations, there are
different percentages published in the literature. Recurrent miscarriage
before 10 weeks is considered the most prevalent obstetric complication
(38.6%) in our registry, followed by foetal loss (25.3%) and stillbirth
(23%). In fact, there is an average of 2.2 non-evolutive pregnancies per
patient with an SD of 1.6 in our study cohort. Analysing current preg-
nancies, we observed that premature births (20.6%) due to PE and FGR
or both are more prevalent that in the previous poor outcomes. This is
partly because there is a higher rate of treatment in current pregnan-
cies, observing a delay in the clinical appearance.
With regard to the miscarriages, we suggest a more accurate defi-
nition; to our knowledge, miscarriage could be classified as early mis-
carriage (or embryonic loss) when it occurs before 10 gestational weeks
and fetal loss when it occurs after 10 gestational weeks [35]. It has also
been suggested that pre-embryonic and embryonic losses could be early
markers of embryo aPL-related injury. However, and attending to the
Sapporo and Sydney criteria, the only morphologically well-formed
embryo inclusion minimises the probability of chromosomal abnorm-
alities. Ectopic, molar, and biochemical pregnancies were not included
[36]. We have found that it is the most prevalent clinical manifestation
in our population, in both previous and historical episodes. This is in
line with what was published by other authors, in which women with
aPL could have a higher rate of early pregnancy loss [37]. Reviewing
the different associations according to the laboratory categories, we
have a homogeneous distribution and we have observed a strong
association between category I and category IIa, with recurrent mis-
carriages and foetal losses respectively. Interestingly, examining poor
obstetric outcomes, there is a significant increase of recurrent mis-
carriages in the presence of category IIb. Moreover, other studies
yielded similar results [38], in spite of both different inclusion criteria
and positive laboratory aPL results. Otherwise, when we focus on the
manifestations related to placental insufficiency, we observed a strong
association between different laboratory categories and PE (around
15–20% with categories I and IIa, and 10–15% with categories IIb and
IIc). Also, the correlation is clear in the case of FGR, where 14–20% of
the association is with category I, IIa and IIc and a minor association
with category IIb (6–10%). This placental dysfunction may also reflect
excessive inflammation driven by the activation of complement with
the consequent endothelial injury [39], and also by aPL signaling Toll-
like receptors 4 (TLR4) on extravillous trophoblast, increasing the se-
cretion of pro-inflammatory cytokines [40]. As we have seen in our
registry, several positivity for aPL revealed a strong association with PE
in another publication [41]. Moreover, prospective and retrospective
studies have observed that the persistent presence of high aPL titer is
associated with preterm deliveries and FGR [42].
All laboratory categories are represented in the OAPS registry.
Classically, triple and double positivity are related to poor obstetric
manifestations, whereas a single positivity is poorly related to them
[43]. On the contrary, in our registry we found a strong association
between all laboratory categories and obstetric complications regard-
less the degree of positivity. We found that category I was linked to RM
in 34.7% cases, prematurity in 30.3%, foetal loss in 28.6% and stillbirth
in 22.1%. According to our registry, we can state that category IIa (the
most prevailing in our registry) shows a robust association with RM in
38.2% of cases, prematurity 31.5%, stillbirth 24.4% and foetal loss
22.2%. Among the other categories, despite the smaller number of
cases, a high frequency of obstetric complications were also showed
(i.e., category IIb had a high rate of RM of 46.9%, while category IIc
had the highest rate of early FGR with 22.2% of the affected cases).
Nevertheless, some authors argue that there is no clear association with
aCL antibodies [44]. In a similar way, Andreoli et al. said that not all
the patients carrying anti-β2GPI develop aPL-related clinical events
[45], although this might be linked to the fact that several epitopes of
β2GPI can be targeted by specific aPL [46]. Nevertheless, the debate on
this topic is ongoing [47] and we will probably be in need of massive
registries to evaluate one by one the different aPL with their kinetics
and clinical implications. At this point, we should add that in usual
clinical practice many aPL analyses are done with concurrent treat-
ments. Therefore, it is necessary to standardise assays in order to avoid
overdiagnosis, especially in the era of direct anticoagulants [48].
Interestingly, 15.9% of cases had an inherited trombophilic disorder
(ITD). Similar results exist in another aPL Caucasian series [49]. Cur-
rently, there is a controversy within ITD and OAPS patients. As pre-
viously mentioned [15], we have not found any association between
these entities and a high rate of thrombosis. In concurrence with our
results, Berman el al. [49] did not find an increased risk of developing
thrombotic phenomena in these patients either. In contrast, other au-
thors as Diz-Kucukkaya et al. [50] found that the presence of the
Leyden Factor V mutation may define a small group of patients who had
a high risk of thrombosis. Conversely, over the past few years, a theory
has appeared that shows a link between circulating microparticles
(MPs) and thrombosis, especially in APS and inherited trombophilia
cases [51]. In this line, there are two studies [52,53] that establish this
relationship in both primary and obstetric APS. None of these studies
found differences in the number of MPs types in either entity.
Our study has also examined the role played by the complement
pathway in the pathogenesis of OAPS. Several authors have demon-
strated this relationship, reinforcing the theory that complement acti-
vation (that induces a pro inflammatory state) predicts adverse preg-
nancy outcomes [54,55]. However, in the EUROAPS registry we only
found 14–16% of patients with low complement values (less than
Table 8
Placental histopathological findings n/N/N (%).
Placental biopsy 159/1000 (15.9)
Normal 35/159 (22.01)
Pathological 124/159 (77.98)
Infarcts 68/124/159 (54.83) (42.76)
Fibrin 37/124/159 (29.83) (23.27)
Thrombus 30/124/159 (24.19) (18.86)
Villitis 28/124/159 (22.58) (17.61)
Choriangiosis 15/124/159 (12.09) (9.43)
Calcifications 11/124/159 (8.87) (6.91)
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expected), possibly due to the lack of information in some patients. In
the same line, we have observed a high frequency of vitamin D deficit
(21.4% of patients), suggesting an involvement in the OAPS generation
[56,57].
To conclude, we would like to highlight the good results achieved in
the comparative between different treatment schedules (Table 7). Ac-
tually, despite the fact that many authors recommend the combination
of preconceptional LDA and a prophylactic dose of LMWH from the first
trimester on [58,59], other recent publications pose that there still exist
many controversies which prevent their use from being standardised
[60]. Nonetheless, we can say that the high rate of good foetal maternal
outcomes and the fewer obstetric complications observed in the treated
group requires clinicians to think about a standardised schedule for all
OAPS patients.
5. Conclusion
Recurrent first trimester miscarriage followed by prematurity and
foetal loss were the most common obstetric morbidities in this cohort.
All laboratory categories and isotypes are represented in our registry,
obtaining a strong correlation between all of them and obstetric com-
plications. A high rate of histopathological findings did not contain
thrombosis, highlighting antiphospholipid obstetric syndrome as a
mixed inflammatory and thrombotic entity. Maternal and foetal out-
comes were excellent when the recommended therapy was used.
EUROAPS project is the biggest published European registry on
obstetric antiphospholipid syndrome and it is ongoing. We consider
that collaboration between specialized centers, sharing information and
discussing the established diagnostic criteria could improve the medical
prognosis of OAPS patients.
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